|
Control group
|
Patient group
|
---|
HPV 16 group
|
HPV 18 group
|
---|
Alleles
|
n (%)
|
n
(%)
|
OR(95% CI)
|
n
(%)
|
OR(95% CI)
|
14 bp In/Del
|
In
|
108(29.2)
|
83(31.9)
|
1.14(0.81–1.60)
|
100(38.5)
|
1.52(1.08–2.12)
a
|
Del
|
262(70.8)
|
177(68.1)
|
0.88(0.62–1.24)
|
160(61.5)
|
0.66(0.47–0.92)
a
|
n
|
370
|
260
| |
260
| |
+3142 C/G
|
C
|
159(43.0)
|
109(41.9)
|
0.96(0.69–1.32)
|
71(27.3)
|
0.50(0.36–0.70)
b
|
G
|
211(57.0)
|
151(58.1)
|
1.04(0.75–1.44)
|
189(72.7)
|
2.01(1.43–2.82)
b
|
n
|
370
|
260
| |
260
| |
Genotypes
|
14 bp In/Del
|
In/In
|
13(7.0)
|
13(10.0)
|
1.47(0.66–3.28)
|
16(12.3)
|
1.86(0.87–3.98)
|
In/Del
|
82 (44.3)
|
57(43.8)
|
0.98(0.62–1.54)
|
68(52.3)
|
1.38(0.88–2.16)
|
Del/Del
|
90(48.7)
|
60(46.2)
|
0.90(0.57–1.42)
|
46(35.4)
|
0.58(0.36–0.92)
c
|
n
|
185
|
130
| |
130
| |
+3142 C/G
|
C/C
|
39(21.1)
|
25(19.2)
|
0.89(0.51–1.56)
|
8(6.2)
|
0.25(0.12–0.52)
d
|
C/G
|
81(43.8)
|
59(45.4)
|
1.07(0.68–1.68)
|
55(42.3)
|
0.94(0.60–1.48)
|
G/G
|
65(35.1)
|
46(35.4)
|
1.01(0.63–1.62)
|
67(51.5)
|
1.96(1.24–3.10)
e
|
n
|
185
|
130
| |
130
| |
Haplotypes
|
In/G
|
108(29.2)
|
83(31.9)
|
1.14(0.81–1.60)
|
100(38.5)
|
1.52(1.08–2.12)
f
|
Del/G
|
103(27.8)
|
68(26.2)
|
0.92(0.64–1.31)
|
89(34.2)
|
1.35(0.96–1.90)
|
Del/C
|
159(43.0)
|
109(41.9)
|
0.96(0.69–1.32)
|
71(27.3)
|
0.50(0.35–0.70)
g
|
n
|
370
|
260
| |
260
| |
- Significant association is highlighted in bold
- CI confidence interval, OR odds ratio
- aχ2 = 5.94, P = 0.015
- bχ2 = 16.17, P = 0.000
- cχ2 = 5.48, P = 0.019
- dχ2 = 13.40, P = 0.000
- eχ2 = 8.44, P = 0.004
- fχ2 = 5.94, P = 0.015
- gχ2 = 16.17, P = 0.000